Accuracy of the SEVEN® continuous glucose monitoring system: Comparison with frequently sampled venous glucose measurements

Journal of Diabetes Science and Technology

Volumn 3, Issue 5, 2009, Pages 1146-1154

  Zisser, Howard C ^a   Bailey, Timothy S ^b   Schwartz, Sherwyn ^c   Ratner, Robert E ^d   Wise, Jonathan ^e  

^a University of California   (United States)

^b Advanced Metabolic Care + Research   (United States)

^c Diabetes and Glandular Disease Clinic   (United States)

^d MEDSTAR RESEARCH INSTITUTE   (United States)

^e Diabetes and Metabolism Associates   (United States)

Author keywords

7 day glucose sensor; Clinical accuracy; Continuous error grid; Continuous glucose monitoring

Indexed keywords

ANTIDIABETIC AGENT; INSULIN;

ADOLESCENT; ADULT; AGED; BLOOD; BLOOD GLUCOSE MONITORING; BLOOD SAMPLING; CALIBRATION; CARBOHYDRATE DIET; CATHETERIZATION; CLINICAL TRIAL; COMPARATIVE STUDY; EQUIPMENT; EQUIPMENT DESIGN; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; INSTRUMENTATION; INSULIN DEPENDENT DIABETES MELLITUS; MALE; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; NOTE; PREDICTION AND FORECASTING; PROSPECTIVE STUDY; REPRODUCIBILITY; STANDARD; TIME; UNITED STATES;

ADOLESCENT; ADULT; AGED; BLOOD GLUCOSE; BLOOD GLUCOSE SELF-MONITORING; BLOOD SPECIMEN COLLECTION; CALIBRATION; CATHETERIZATION, PERIPHERAL; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIAGNOSTIC EQUIPMENT; DIETARY CARBOHYDRATES; EQUIPMENT DESIGN; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; REPRODUCIBILITY OF RESULTS; TIME FACTORS; UNITED STATES; YOUNG ADULT;

EID: 77953054702     PISSN: None     EISSN: 19322968     Source Type: Journal    
DOI: 10.1177/193229680900300519     Document Type: Article

References (36)

1. Skyler JS. The economic burden of diabetes and the benefits of improved glycemic control: the potential role of a continuous glucose monitoring system. Diabetes Technol Ther. 2000;2 Suppl. 1:S7-12.
2. Klonoff DC. Continuous glucose monitoring: roadmap for 21st century diabetes therapy. Diabetes Care. 2005;28(5):1231-9. (Pubitemid 40616646)
3. Buckingham B, Block J, Wilson DM. Continuous glucose monitoring. Curr O pin Endocrinol Diabetes. 2005;12:273-9. (Pubitemid 41225235)
4. Bailey T, Zisser H, Garg S. Reduction in reduction in hemoglobin A1c with real-time continuous glucose monitoring: results from a 12-week observational study. Diabetes Technol Ther. 2007;9(3):203-9.
5. Garg S, Jovanovic L. Relationship of fasting and hourly blood glucose levels to HbA1c values: safety, accuracy, and improvements in glucose profiles obtained using a 7-day continuous glucose sensor. Diabetes Care. 2005;29(12):2644-9. (Pubitemid 44912192)
6. Chase HP, Kim LM, O wen SL, MacKenzie TA, Klingensmith GJ, Murtfeldt R, Garg SK. Continuous subcutaneous glucose monitoring in children with type 1 diabetes. Pediatrics. 2001;107(2):222-6. (Pubitemid 32121233)
7. Chase HP, Roberts MD, Wightman C, Klingensmith G, Garg SK, Van Wyhe M, Desai S, Harper W, Lopatin M, Bartkowiak M, Tamada J, Eastman RC. Use of the GlucoWatch Biographer in children with type 1 diabetes. Pediatrics. 2003;111(4 Pt 1):790-4. (Pubitemid 36402903)
8. Ludvigsson J, Hanas R. Continuous subcutaneous glucose monitoring improved metabolic control in pediatric patients with type 1 diabetes: a controlled crossover study. Pediatrics. 2003;111(5 Pt 1):933-8. (Pubitemid 36542603)
9. Tanenberg R, Bode B, Lane W, Levetan C, Mestman J, Harmel AP, Tobian J, Gross T, Mastrototaro J. Use of the continuous glucose monitoring system to guide therapy in patients with insulin-treated diabetes: a randomized controlled trial. Mayo Clin Proc. 2004;79(12):1521-6. (Pubitemid 39578876)
10. Bode BW, Gross TM, Thornton KR, Mastrototaro JJ. Continuous glucose monitoring used to adjust diabetes therapy improves glycosylated hemoglobin: a pilot study. Diabetes Res Clin Pract. 1999;46(3):183-90.
11. Schiaffini R, Ciampalini P, Fierabracci A, Spera S, Borrelli P, Bottazzo GF, Crino A. The Continuous Glucose Monitoring System (CGMS) in type 1 diabetic children is the way to reduce hypoglycemic risk. Diabetes Metab Res Rev. 2002;18(4):324-9.
12. Schaepelynck-Belicar P, Vague P, Simonin G, Lassmann-Vague V. Improved metabolic control in diabetic adolescents using the continuous glucose monitoring system (CGMS). Diabetes Metab. 2003;29(6):608-12. (Pubitemid 38082163)
13. Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group, Tamborlane WV, Beck RW, Bode BW, Buckingham B, Chase HP, Clemons R, Fiallo-Scharer R, Fox LA, Gilliam LK, Hirsch IB, Huang ES, Kollman C, Kowalski AJ, Laffel L, Lawrence JM, Lee J, Mauras N, O'Grady M, Ruedy KJ, Tansey M, Tsalikian E, Weinzimer S, Wilson DM, Wolpert H, Wysocki T, Xing D. Continuous glucose monitoring and intensive treatment of type 1 diabetes. N Engl J Med. 2008;359(14):1464-76.
14. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329(14):977-86.
15. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352(9131):854-65.
16. Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: the Epidemiology of Diabetes Interventions and Complications (EDIC) study. JAMA. 2003;290(16):2159-67.
17. Nathan DM, Cleary PA, Backlund JY, Genuth SM, Lachin JM, Orchard TJ, Raskin P, Zinman B; Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med. 2005;353(25): 2643-53. (Pubitemid 41817713)
18. The Diabetes Control and Complications Trial Research Group. The relationship of glycemic exposure (HbA1c) to the risk of development and progression of retinopathy in the diabetes control and complications trial. Diabetes. 1995;44(8):968-83.
19. Hirsch IB, Brownlee M. Should minimal blood glucose variability become the gold standard of glycemic control? J Diabetes Complications. 2005;19(3):178-81. (Pubitemid 40615551)
20. Monnier L, Mas E, Ginet C, Michel F, Villon L, Cristol J, Colette C. Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. JAMA. 2006;295(14):1681-7.
21. Brownlee M, Hirsch IB. Glycemic variability: a hemoglobin A1c-independent risk factor for diabetic complications. JAMA. 2006;295(14):1707-8.
22. The Diabetes Research in Children Network (DirecNet) Study Group. The accuracy of the CGMS in children with type 1 diabetes: results of the Diabetes Research in Children Network (DirecNet) accuracy study. Diabetes Technol Ther. 2003;5(5):781-9.
23. Chia CW, Saudek CD. Glucose sensors: toward closed loop insulin delivery. Endocrinol Metab Clin North Am. 2004;33(1):175-95, xi. (Pubitemid 38438430)
24. Hovorka R. Continuous glucose monitoring and closed-loop systems. Diabet Med. 2006;23(1):1-12.
25. U.S. Food and Drug Administration. Summary of safety and effectiveness data: Medtronic Guardian RT [article online], 2006 [cited 2008 Sep 4]. Available from: http://www.fda.gov/cdrh/PDF/p980022s011b.pdf.\
26. U.S. Food and Drug Administration. Summary of safety and effectiveness data: DexCom STS continuous glucose monitoring system [article online], 2007[cited 2008 Sep 4]. Available from: http://www.fda.gov/cdrh/pdf5/p050012b. pdf.
27. U.S. Food and Drug Administration. Summary of safety and effectiveness data: Abbott Freestyle Navigator [article online], 2008 [cited 2008 Sep 4]. Available from: http://www.fda.gov/cdrh/pdf5/p050020b.pdf.
28. Garg S, Zisser H, Schwartz S, Bailey T, Kaplan R, Ellis S, Jovanovic L. Improvement in glycemic excursions with a transcutaneous, real-time continuous glucose sensor: a randomized controlled trial. Diabetes Care. 2006; 29(1):44-50. (Pubitemid 44033429)
29. Deming WE. Statistical adjustment of data. New York: Dover; 1964.
30. Brauker J, Kamath A, Li Y, Zisser H, Schwartz S, Ratner R, Wise J, Bailey TS. Time lag of a seven-day transcutaneous continuous glucose sensor compared to YSI blood glucose values [poster]. The 67th Scientific Sessions of the American Diabetes Association, Chicago, IL; 2007.
31. Cox DJ, Clarke WL, Gonder-Frederick L, Pohl S, Hoover C, Snyder A, Zimbelman L, Carter WR, Bobbitt S, Pennebaker J. Accuracy of perceiving blood glucose in IDDM. Diabetes Care. 1985;8(6):529-36. (Pubitemid 16194474)
32. Clarke WL, Cox D, Gonder-Frederick LA, Carter W, Pohl SL. Evaluating clinical accuracy of systems for self-monitoring of blood glucose. Diabetes Care. 1987;10(5):622-8. (Pubitemid 17158937)
33. Kovatchev BP, Gonder-Frederick LA, Cox DJ, Clarke WL .? Evaluating the accuracy of continuous glucose-monitoring sensors: continuous glucose-error grid analysis illustrated by TheraSense Freestyle Navigator data. Diabetes Care. 2004;27(8):1922-8. (Pubitemid 38989233)
34. Weinstein R, Schwartz SL, Brazg RL, Bugler JR, Peyser TA, McGarraugh GV. Accuracy of the 5-Day Freestyle Navigator Continuous Glucose Monitoring System: comparison with frequent laboratory reference measurements. Diabetes Care. 2007;30(5):1125-30. (Pubitemid 46684636)
35. Garg SK, Smith J, Beatson C, Lopez-Baca B, Voelmle M, Gottlieb PA.? Comparison of accuracy and safety of the SEVEN and the Navigator continuous glucose monitoring systems. Diabetes Technol Ther. 2009;11(2):65-72.
36. Bailey T, Zisser H, Chang A, Li D, Jones K, Garg SK. Performance of the DexCom SEVEN continuous glucose monitoring system with manual entry of calibration blood glucose values [abstract 19999-PO]. Diabetes. 2008;57 (Suppl 1):A552.